Antibiotic therapy augments the efficacy of gemcitabine-containing regimens for advanced cancer: a retrospective study
Authors Imai H, Saijo K, Komine K, Otsuki Y, Ohuchi K, Sato Y, Okita A, Takahashi M, Takahashi S, Shirota H, Takahashi M, Ishioka C
Received 14 May 2019
Accepted for publication 16 July 2019
Published 22 August 2019 Volume 2019:11 Pages 7953—7965
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 2
Editor who approved publication: Professor Rudolph Navari
Hiroo Imai,1 Ken Saijo,1 Keigo Komine,1 Yasufumi Otsuki,2 Kota Ohuchi,1 Yuko Sato,1 Akira Okita,2 Masahiro Takahashi,1 Shin Takahashi,2 Hidekazu Shirota,1 Masanobu Takahashi,2 Chikashi Ishioka2
1Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan; 2Department of Clinical Oncology, Institute of Developing, Aging and Cancer, Tohoku University, Sendai, Japan
Correspondence: Chikashi Ishioka
Department of Medical Oncology, Tohoku University Hospital, 4-1, Seiryo-machi, Aobaku, Sendai 980-8575, Japan
Tel +81 22 717 8543
Fax +81 22 717 8548
Background: The addition of antibiotics reportedly augments the efficacy of gemcitabine (GEM) in tumor-bearing mice. However, whether this phenomenon is also observed in cancer patients remains unclear. In the present study, we aimed to assess whether antibiotics for treatment or prevention of infection augments treatment efficacies of GEM-containing regimens in patients with any type of cancer.
Methods: Medical records of patients diagnosed with cancer histopathologically and treated with GEM-containing regimens (n=169) were retrospectively reviewed. Patients were assigned into two groups: antibiotics-untreated group (patients who were treated with GEM-containing regimens but without antibiotics) and antibiotics-treated group (patients who were treated with GEM-containing regimens plus antibiotics). Response rates, progression-free survival (PFS) time, and overall survival (OS) time were analyzed for each group.
Results: The response rates of the antibiotics-untreated and antibiotics-treated groups with GEM-containing regimens were 15.1% and 27.6%, respectively. The median PFS times of the antibiotics-untreated and antibiotics-treated groups were 2.5 (95% CI: 1.86–3.73) and 4.9 (95% CI: 3.47–6.0) months, respectively. The median OS times of the antibiotics-untreated and antibiotics-treated groups were 7.53 (95% CI: 5.63–9.57) months and 13.83 (95% CI: 10.83–16.43) months, respectively.
Conclusion: The addition of antibiotics augments the treatment efficacies of GEM-containing regimens, and it may be a potential therapeutic option to improve treatment efficacies of GEM-containing regimens in patients with advanced cancer.
Keywords: antibiotics, bacteria, gemcitabine, multivariate analysis, univariate analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]